Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubenimex - Delta-Fly Pharma

Next Previous
Drug Profile

Ubenimex - Delta-Fly Pharma

Alternative Names: DFP-14323

Latest Information Update: 09 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Delta-Fly Pharma
  • Class Antineoplastics; Branched-chain amino acids; Dipeptides; Essential amino acids; Immunotherapies; Small molecules
  • Mechanism of Action CD13 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 03 Jul 2024 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease) in Japan (PO)
  • 02 Feb 2024 Ubenimex - Delta-Fly Pharma is available for licensing in (excluding Japan) as of 02 Feb 2024. https://www.delta-flypharma.co.jp/en/r-and-d/
  • 02 Feb 2024 Pharmaceuticals and Medical Devices Agency (PMDA) approves the phase III trial of DFP 14323 for non-small cell lung cancer in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top